explore -WSS

explore

author：leisure time 2025-09-30 11:58:33 - browse：6

Duchenne muscular dystrophy Histopathology — Duchenne muscular dystrophy histopathology. Dr. Edwin P. Ewing, Jr./CDC

Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease, had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

Children who received the drug could stand up faster from the floor at the end of the study, but so could children who received a placebo. There was no statistically significant difference between the groups.

Although Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of drugs called exon-skippers. Duchenne is caused by mutations in a muscle-supporting gene called dystrophin. These drugs are designed to increase the amount of dystrophin protein that patients with specific mutations produce. But the drugs only lead to slight increases in protein levels, and their clinical benefits have never been proven in a large, placebo-controlled study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Lilly’s obesity pill cuts 15% of weight at highest dose in mid

WSS

Illumina to lay off 10% of research and development team

FDA panel signals lack of confidence in Amgen cancer drug data

VC firm General Catalyst wants to buy a health system

Newly formed Hurricane Beatriz sweeps close to Mexico's southwest Pacific coast

Sana to lay off nearly a third of staff, de

AI can decode, harness the power of the humane immune system

entertainment

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Apple is now the first public company to be valued at $3 trillion

Why Charlie Gard's case is so disturbing to Americans

Trump demands the U.S. pay no more for drugs than other countries … again

Phenylephrine and the overlooked value of the placebo effect

Drug repurposing or repositioning? The language matters

Senate panel eyes new effort on drug shortages

Medical leaders decry Supreme Court decision on affirmative action

Brazil's Jair Bolsonaro is barred from running for office until 2030

23andMe had bad news about my health. I wish a person had delivered it

AI can decode, harness the power of the humane immune system

hotspot

Wildfire smoke map: Which US cities are forecast to be impacted by fires burning in Canada

The simple reason for the increase in autism diagnosis

Was Amgen transparent enough on FDA's concern on cancer drug?

Ukrainian soldiers say they owe lives to US

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Stroke deaths set to near 10 million globally by 2050

entertainment

knowledge

explore

Wikipedia